UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTER ENDED SEPTEMBER 30, 2009

0-28092
(Commission file number)

Medical Information Technology, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Massachusetts
(State of Incorporation)

04-2455639
(IRS Employer Identification Number)

Meditech Circle, Westwood, MA
(Address of Principal Executive Offices)

02090
(Zip Code)

781-821-3000
(Registrant's Telephone Number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ ] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [X] Smaller reporting company [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [ ] No [X]

There were 35,702,426 shares of Common Stock, $1.00 par value, outstanding at September 30, 2009.

Page 1 of 11

Index to Form 10-Q	Page
Part I - Financial Information
Item 1 - Consolidated Financial Statements (Unaudited)
Consolidated Balance Sheet as of December 31, 2008 and September 30, 2009	3
Consolidated Income Statement for Three and Nine Months Ended September 30, 2008	4
and 2009
Consolidated Cash Flow Statement for Nine Months Ended September 30, 2008 and 2009	5
Notes To Consolidated Financial Statements	6
Item 2 - Management's Discussion and Analysis of Operating Results and Financial Condition	9
Item 3 - Quantitative and Qualitative Disclosures About Market Risk	10
Item 4 - Controls and Procedures	10
Part II - Other Information
Item 1 - Legal Proceedings	11
Item 1A - Risk Factors	11
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds	11
Item 3 - Defaults Upon Senior Securities	11
Item 4 - Submission of Matters to a Vote of Shareholders	11
Item 5 - Other Information	11
Item 6 - Exhibits	11
Signatures	11

Page 2 of 11

Item 1 - Consolidated Financial Statements (Unaudited)

Consolidated Balance Sheet as of December 31, 2008 and September 30, 2009

	Dec 31, 2008	Sep 30, 2009
Cash and equivalents	$12,964,756	$23,646,267
Marketable securities	152,402,588	181,815,041
Accounts receivable, less reserves	47,569,950	47,710,697
Deferred taxes	14,841,263	13,395,282
Current assets	227,778,557	266,567,287
Computer equipment	9,513,945	9,420,768
Furniture and fixtures	42,068,652	42,445,847
Buildings	179,396,034	179,396,034
Land	33,407,959	33,407,959
Accumulated depreciation	(94,083,882)	(99,516,642)
Fixed assets	170,302,708	165,153,966
Marketable securities	20,000,000	0
Other assets	12,503,180	12,802,204
Total assets	$430,584,445	$444,523,457
Accounts payable	$625,326	$4,093,606
Taxes payable	3,165,313	2,432,466
Accrued expenses	33,967,110	29,821,466
Customer deposits	24,239,540	29,079,800
Tax reserves	15,218,983	14,683,983
Total liabilities	77,216,272	80,111,321
Common stock, $1.00 par value,
authorized 40,000,000 shares,
issued and outstanding 35,687,426
in 2008 and 35,702,426 in 2009	35,687,426	35,702,426
Additional paid-in capital	62,290,657	62,830,657
Retained income	267,569,536	258,177,346
Unrealized security (loss) gain, net of tax	(12,179,446)	7,701,707
Shareholder equity	353,368,173	364,412,136
Total liabilities and shareholder equity	$430,584,445	$444,523,457

Page 3 of 11

Consolidated Income Statement for Three and Nine Months Ended September 30, 2008 and 2009

	3 months	ended on	9 months	ended on
	Sep 30, 2008	Sep 30, 2009	Sep 30, 2008	Sep 30, 2009
Product revenue	$49,521,765	$41,679,314	$144,455,786	$124,895,838
Service revenue	51,067,489	54,713,355	150,099,597	161,668,878
Total revenue	100,589,254	96,392,669	294,555,383	286,564,716
Operations, development	45,406,484	46,365,524	135,552,242	139,032,443
Selling, G & A	21,946,945	20,487,361	64,086,544	60,989,073
Operating expense	67,353,429	66,852,885	199,638,786	200,021,516
Operating income	33,235,825	29,539,784	94,916,597	86,543,200
Other (loss) income	(44,920,165)	4,058,776	(41,612,949)	9,888,428
Other expense	2,148,216	1,730,399	6,381,386	5,394,659
Pretax income	(13,832,556)	31,868,161	46,922,262	91,036,969
State income tax	2,499,990	2,611,251	7,111,710	7,276,752
Federal income tax	10,731,971	8,770,756	29,077,132	25,684,269
Income tax	13,231,961	11,382,007	36,188,842	32,961,021
Net (loss) income	($27,064,517)	$20,486,154	$10,733,420	$58,075,948

Page 4 of 11

Consolidated Cash Flow Statement for Nine Months Ended September 30, 2008 and 2009

	9 months	ended on
	Sep 30, 2008	Sep 30, 2009
Net income	$10,733,420	$58,075,948
Depreciation expense	7,232,706	7,406,263
Write-down of marketable securities	65,016,345	1,725,000
Reversal of prior write-downs	(3,483,834)	0
Gain on sales of marketable securities	(7,126,111)	(41,799)
Deferred taxes on unrealized securities loss (gain)	5,536,037	(1,952,165)
Change in accounts receivable	(8,720,850)	(140,747)
Change in accounts payable	3,795,380	3,468,280
Change in taxes payable	(1,192,213)	(732,847)
Change in accrued expenses	(2,080,425)	(4,145,645)
Change in customer deposits	721,803	4,840,260
Change in deferred taxes and tax reserves	(10,186,198)	910,982
Net cash from operations	60,246,060	69,413,530
Purchases of marketable securities	(49,527,010)	(37,303,340)
Sales of marketable securities	47,086,845	48,041,000
Purchases of fixed assets	(10,574,192)	(2,257,521)
Change in other assets	848,615	(299,024)
Net cash (used in) from investing	(12,165,742)	8,181,115
Sales of common stock	7,627,735	555,000
Dividends paid	(67,319,355)	(67,468,134)
Net cash used in financing	(59,691,620)	(66,913,134)
Net change in cash and equivalents	(11,611,302)	10,681,511
Cash and equivalents at beginning	22,567,940	12,964,756
Cash and equivalents at end	$10,956,638	$23,646,267

Page 5 of 11

Notes To Consolidated Financial Statements

1. The unaudited consolidated financial statements presented herein have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by generally accepted accounting principles. These statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2008 included in MEDITECH's Form 10-K/A filed on February 13, 2009. The unaudited financial statements presented herein have not been audited by our Independent Registered Public Accounting Firm in accordance with the standards of the Public Company Accounting Oversight Board (United States), but in the opinion of management such financial statements include all normal recurring adjustments necessary to present fairly MEDITECH's financial position, operating results and cash flow.

2. MEDITECH follows the provisions of Accounting Standards Codification (ASC) 260-10, Earnings per Share. ASC 260-10 requires reporting both basic and diluted earnings per share. MEDITECH has no common share equivalents such as preferred stock, warrants or stock options which would dilute earnings per share. Thus, earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the applicable period.

	3 months	ended on	9 months	ended on
	Sep 30, 2008	Sep 30, 2009	Sep 30, 2008	Sep 30, 2009
Net (loss) income	($27,064,517)	$20,486,154	$10,733,420	$58,075,948
Average number of shares	35,664,520	35,699,093	35,664,520	35,699,093
Earnings per share	($0.76)	$0.57	$0.30	$1.63

The average number of shares outstanding during the periods reflects the issuance of 206,155 shares in February 2008 pursuant to the 2004 Stock Purchase Plan and the issuance of 15,000 shares sold to a Director in February 2009.

3. MEDITECH follows the provisions of ASC 320-10, Investments - Debt and Equity Securities. ASC 320-10 requires companies to classify their investments as trading, available-for-sale or held-to-maturity. MEDITECH's marketable securities consist of common and preferred equities which have been classified as available-for-sale. These are recorded in the financial statements at fair value and any unrealized gains or losses, net of tax, are reported as a component of shareholder equity. The fair value of marketable securities was determined based on quoted prices in active markets. In addition MEDITECH holds bank and government notes which have been classified as held-to-maturity. These are recorded in the financial statements at their cost which approximates their fair value.

ASC 320-10 requires that for each individual security classified as available-for-sale, a company shall determine whether a decline in fair value below the cost basis is other-than-temporary. If the decline in fair value is judged as such, the cost basis of the individual security shall be reduced to fair value and the amount of the write-down shall be reflected in earnings. During the 1st quarter 2009 MEDITECH determined the decline in fair value of 6 equity issues to be other-than-temporary and reduced their cost basis by $1,725,000 to bring it in line with fair value.

Beginning in the fourth quarter of 2008, MEDITECH began to evaluate its preferred securities for other-than-temporary impairment using an impairment model consistent with a debt security. This change in practice is in accordance with new accounting guidance related to these instruments, issued in a letter from the SEC to the Financial Accounting Standards Board, dated October 14, 2008. Unlike equity securities, which use a "near term" period of recoverability when assessing impairment (usually six months), the assessment period for impairment of debt securities is dependent on the investor's ability and intent to hold the security until recovery, as well as an evaluation of the credit worthiness of the issuer.

Page 6 of 11

Effective April 1, 2009 MEDITECH adopted the provisions of ASC 320-10-35, Subsequent Measuremant. ASC 320-10-35 changes existing accounting requirements under ASC 320-10 for measuring such impairment of debt securities, adds new disclosures, and extends disclosure requirements to interim reporting periods.

At September 30, 2009 MEDITECH's marketable securities had an adjusted cost basis of $174,113,335 and a fair value of $181,815,041. The difference included gross unrealized gains of $11,936,380 and gross unrealized losses of $4,232,672, which have been accounted for within comprehensive income. Most of the securities in loss status are preferred securities issued by large financial institutions. None of these securities have been in a loss status for more than 20 months. All have improved significantly and none have a loss greater than 12%.

MEDITECH has evaluated the unrealized losses as of September 30, 2009 in accordance with this new guidance, and has concluded that the unrealized losses are temporary in nature. The factors that MEDITECH considered included the severity and duration of the loss, MEDITECH's intent and ability to hold these securities for an extended period of time until recovery, and that all of the issuers are current on dividend payments and maintain investment grade ratings. MEDITECH also considered the effect of fluctuating interest rates, current economic and industry conditions, and the issuers' current financial position in order to reach its conclusion that these impairments were temporary at September 30, 2009. MEDITECH continues to evaluate whether the situation warrants further write-downs.

4. MEDITECH follows the provisions of ASC 220-10, Comprehensive Income. ASC 220-10 establishes standards for reporting and display of comprehensive income and its components in financial statements. Comprehensive income is the total of net income and all other non-owner changes in equity including items such as net unrealized gains or losses on marketable securities classified as available-for-sale, foreign currency translation adjustments and minimum pension liability adjustments.

	3 months	ended on	9 months	ended on
	Sep 30, 2008	Sep 30, 2009	Sep 30, 2008	Sep 30, 2009
Net (loss) income	($27,064,517)	$20,486,154	$10,733,420	$58,075,948
Net unrealized securities (loss) gain	(3,900,098)	14,482,337	(8,304,055)	19,981,153
Comprehensive income	($30,964,615)	$34,968,491	$2,429,365	$78,057,101

5. MEDITECH follows the provisions of ASC 323-10, Investments - Equity Method and Joint Ventures, and as such, accounts for the equity investments in LSS Data Systems Inc. and MEDITECH South Africa in accordance with the cost method. Both companies license MEDITECH's software technology and re-license it to their respective customers. Each serves a market niche which is part of the overall medical market but is outside of the hospital market which MEDITECH serves. Included in these investments are the $1,960,000 balance on a mortgage note from LSS Data Systems Inc. and the $1,119,500 balance on a mortgage note from MEDITECH South Africa, both of which are fully collateralized by land and buildings owned and occupied as corporate headquarters by the borrowers. MEDITECH believes the fair value of these investments which are included in other assets approximates its carrying value of $7,107,061 at September 30, 2009.

Page 7 of 11

Patient Care Technologies, Inc. (PtCT) is engaged in the development, manufacture and licensing of computer software products and their support for the home health care market. During the 2nd quarter 2007 MEDITECH acquired PtCT which then became a wholly-owned subsidiary of MEDITECH. The financial statements for 2007 and thereafter are presented on a consolidated basis. MEDITECH accounted for this acquisition under the purchase method of accounting in accordance with ASC 805-10, Business Combinations. The values of assets acquired and liabilities assumed, including the identified intangibles, such as developed technology and backlog, and unidentified intangibles are based upon management's estimates of fair value as of the date of acquisition. An acquired deferred tax asset was also recognized to reflect the carryforward of net operating losses expected to be realized.

The identified intangibles were valued at $5,977,801, are being amortized over their 7 year useful lives and are included in other assets. A deferred tax liability was recognized to reflect the tax effect of these identified intangibles as such amounts are not deductible for tax purposes. The unidentified intangibles were valued at $1,211,786, are not amortizable and are also included in other assets. This amount is evaluated annually for impairment. MEDITECH conducted its annual impairment test as of December 31, 2008 and has concluded these assets to be recoverable.

6. MEDITECH follows the provisions of ASC 740-10, Accounting for Income Taxes. Based on the criteria set forth in ASC 740-10, MEDITECH's tax reserves amounted to potential tax assessments of $5,378,971 plus interest and penalties of $9,840,012 at December 31, 2008 and have not changed materially at September 30, 2009. These reserves relate to research tax credit, domestic production activities deduction, and state nexus. The years 2006 through 2008 are subject to examination by the IRS, and various years are subject to examination by state tax authorities.

7. MEDITECH follows the provisions of ASC 280-10, Segment Reporting. Based on the criteria set forth in ASC 280-10, MEDITECH currently operates in one operating segment, medical software and services. MEDITECH derives substantially all of its operating revenue from the sale and support of one group of similar products and services. All of MEDITECH's assets are located within the United States. The following table indicates the operating revenue percentage based on location of customer.

	3 months	ended on	9 months	ended on
Country	Sep 30, 2008	Sep 30, 2009	Sep 30, 2008	Sep 30, 2009
United States	90%	85%	90%	86%
Canada	8%	12%	8%	11%
All others	2%	3%	2%	3%

8. Effective January 1, 2008, MEDITECH adopted the provisions of ASC 820-10, Fair Value Measurement and Disclosures. ASC 820-10 provides for expanded disclosure and guidelines to determine fair market value of assets and liabilities. ASC 820-10 applies whenever other standards require or permit assets and liabilities to be measured at fair value, but does not expand the use of fair value in any new circumstances. MEDITECH's marketable securities represent assets measured at fair value on a recurring basis, and full quantitative disclosure is provided under footnote 3.

9. Effective June 30, 2009 MEDITECH adopted the provisions of ASC 855, Subsequent Events. ASC 855 requires disclosure of the date through which subsequent events have been evaluated, as well as whether that date is the date the financial statements were issued or the date the financial statements were available to be issued. MEDITECH has evaluated subsequent events through October 29, 2009, the date of financial statement issuance.

Page 8 of 11

Item 2 - Management's Discussion and Analysis of Operating Results and Financial Condition

Operating	3 months	ended on	Percent
Results	Sep 30, 2008	Sep 30, 2009	Change
Total revenue	$100,589,254	$96,392,669	(4.2%)
Operating income	33,235,825	29,539,784	(11.1%)
Net (loss) income	(27,064,517)	20,486,154
Average number of shares	35,664,520	35,699,093	0.1%
Earnings per share	($0.76)	$0.57
Cash dividends per share	$0.63	$0.63

Total revenue from both existing and new customers decreased by $4.2 million. It was composed of $7.8 million in reduced product revenue and $3.6 million in additional service revenue.

Operating expense decreased by $0.5 million or 0.7% due primarily to lower staff related travel costs. The resultant operating income decreased by $3.7 million.

Other income increased by $49.0 million due primarily to the prior period's investment impairment. Other expense decreased by $0.4 million due primarily to reduced professional fees. The resultant pretax income increased by $45.7 million.

MEDITECH's effective tax rate of 35.7% decreased substantially due primarily to the prior period's investment impairment without any tax benefit. Net income increased by $47.5 million due primarily to these impairments.

Operating	9 months	ended on	Percent
Results	Sep 30, 2008	Sep 30, 2009	Change
Total revenue	$294,555,383	$286,564,716	(2.7%)
Operating income	94,916,597	86,543,200	(8.8%)
Net income	10,733,420	58,075,948	441.1%
Average number of shares	35,664,520	35,699,093	0.1%
Earnings per share	$0.30	$1.63	440.6%
Cash dividends per share	$1.89	$1.89

Total revenue from both existing and new customers decreased by $8.0 million. It was composed of $19.6 million in reduced product revenue and $11.6 million in additional service revenue.

Operating expense increased by $0.4 million or 0.2% due primarily to higher staff related costs. The resultant operating income decreased by $8.4 million.

Other income increased by $51.5 million due primarily to the prior period's investment impairment. Other expense decreased by $1.0 million due primarily to reduced professional fees. The resultant pretax income increased by $44.1 million.

MEDITECH's effective tax rate of 36.2% decreased substantially due primarily to the prior period's investment impairment without any tax benefit. Net income increased by $47.3 million due primarily to these impairments.

Page 9 of 11

Financial Condition	Dec 31, 2008	Sep 30, 2009
Cash and equivalents	$12,964,756	$23,646,267
Total assets	430,584,445	444,523,457
Total liabilities	77,216,272	80,111,321
Shareholder equity	353,368,173	364,412,136
Outstanding number of shares	35,687,426	35,702,426
Shareholder equity per share	$9.90	$10.21

Accounts payable increased by $3.5 million during the first 9 months primarily because no payroll tax withholding was outstanding at December 31, 2008 while $3.1 million was outstanding at September 30, 2009.

Accrued expenses decreased by $4.1 million during the first 9 months primarily because of the payment of $28.3 million in bonuses applicable to 2008, offset by the accrual of $23.4 million in bonus expenses applicable to 2009.

At September 30, 2009 MEDITECH's cash, cash equivalents and marketable securities totaled $205.5 million. Marketable securities consisted of preferred and common equities plus bank and government notes. For the first 9 months of 2009 cash flow from operations was $69.4 million, cash flow from investing was $8.2 million and cash flow used in financing was $66.9 million. The payment of $67.5 million in dividends to shareholders was the primary use of cash generated by operating activities during the period.

MEDITECH has no long-term debt. Shareholder equity at September 30, 2009 was $364.4 million. Management anticipates additions to fixed assets will continue, including new facilities and computer systems for product development, sales and marketing, implementation, service and administrative staff. Management believes existing cash, cash equivalents and marketable securities together with funds generated from operations will be sufficient to meet operating and capital expense requirements for the foreseeable future.

Item 3 - Quantitative and Qualitative Disclosures About Market Risk

None.

Item 4 - Controls and Procedures

An evaluation was conducted under the supervision and with the participation of MEDITECH's management, including the Chief Executive Officer and Chief Financial Officer, on the effectiveness of MEDITECH's disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)14(c) under the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded MEDITECH's disclosure controls and procedures are, to the best of their knowledge, effective to ensure information requiring disclosure by MEDITECH in reports which it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

There were no changes in MEDITECH's internal control over financial reporting occurring during the fiscal quarter covered by this report which have materially affected or are reasonably likely to materially affect MEDITECH's internal control over financial reporting.

Page 10 of 11

Item 1 - Legal Proceedings

None

Item 1A - Risk Factors

No material changes from risk factors as previously disclosed in MEDITECH's Form 10-K/A filed on February 13, 2009.

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds

Neither MEDITECH nor the Medical Information Technology, Inc. Profit Sharing Trust purchased any shares of MEDITECH's common stock during the 3rd quarter of 2009. However, during the 3rd quarter A. Neil Pappalardo purchased 5,775 shares of MEDITECH's common stock at $37.00 per share for a total of $213,675 in individual private transactions.

Item 3 - Defaults Upon Senior Securities

None.

Item 4 - Submission of Matters to a Vote of Shareholders

None.

Item 5 - Other Information

None.

Item 6 - Exhibits

Exhibit 3.1: MEDITECH's Articles of Organization, as amended to date, are incorporated by reference to an exhibit to the quarterly report on Form 10-Q for the quarter ended March 31, 2007.

Exhibit 3.2: MEDITECH's By-laws, as amended to date, are incorporated by reference to an exhibit to the annual report on Form 10-K for the year ended December 31, 2001.

Exhibit 31: Rule 13a-14(a) Certifications and Exhibit 32: Section 1350 Certifications are appended to this report.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Medical Information Technology, Inc.
(Registrant)

October 29, 2009
(Date)

Barbara A. Manzolillo, Chief Financial Officer and Treasurer
(Signature)

Page 11 of 11

Exhibit 31: Rule 13a-14(a) Certifications

CERTIFICATION PURSUANT TO RULE 13A-14 OR 15D-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Barbara A. Manzolillo, Chief Financial Officer and Treasurer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Medical Information Technology, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

October 29, 2009
(Date)

Barbara A. Manzolillo, Chief Financial Officer and Treasurer
(Signature)

I, A. Neil Pappalardo, Chief Executive Officer and Chairman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Medical Information Technology, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

October 29, 2009
(Date)

A. Neil Pappalardo, Chief Executive Officer and Chairman
(Signature)

Exhibit 32: Section 1350 Certifications

I, Barbara A. Manzolillo, Chief Financial Officer and Treasurer, certify this quarterly report on Form 10-Q of Medical Information Technology, Inc. (MEDITECH) for the period ended September 30, 2009, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of MEDITECH.

October 29, 2009
(Date)

Barbara A. Manzolillo, Chief Financial Officer and Treasurer
(Signature)

I, A. Neil Pappalardo, Chief Executive Officer and Chairman, certify this quarterly report on Form 10-Q of Medical Information Technology, Inc. (MEDITECH) for the period ended September 30, 2009, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of MEDITECH.

October 29, 2009
(Date)

A. Neil Pappalardo, Chief Executive Officer and Chairman
(Signature)